Age-related clonal hematopoiesis

Blood

Volumn 131, Issue 5, 2018, Pages 496-504

  Shlush, Liran I ^a,b,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Rambam Healthcare Campus   (Israel)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

AGE; AGE RELATED CLONAL HEMATOPOIESIS; CANCER MORTALITY; CANCER RISK; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COPY NUMBER VARIATION; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FOLLOW UP; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HERITABILITY; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LABORATORY TEST; MEDICAL HISTORY; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PRELEUKEMIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE CELL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL EXPANSION; VASCULAR DISEASE; AGING; ANIMAL; BLOOD; CELL CLONE; CLONAL EVOLUTION; GENETIC VARIATION; GENETICS; PHYSIOLOGY;

AGING; ANIMALS; CLONAL EVOLUTION; CLONE CELLS; GENETIC VARIATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 85041331936     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-746453     Document Type: Review

References (69)

1. Abkowitz JL, Catlin SN, McCallie MT, Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood. 2002;100(7):2665-2667.
2. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742-752.
3. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA. 1967;58(4):1468-1471.
4. Fialkow PJ. Primordial cell pool size and lineage relationships of five human cell types. Ann Hum Genet. 1973;37(1):39-48.
5. Hitzeroth HW, Bender K, Ropers HH, Geerthsen JM. Tentative evidence for 3--4 haematopoetic stem cells in man. Hum Genet. 1977;35(2):175-183.
6. Hitzeroth HW, Bender K. Age-dependency of somatic selection in South African Negro G-6PD heterozygotes. Hum Genet. 1981;58(3): 338-343.
7. Fey MF, Liechti-Gallati S, von Rohr A, et al. Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood. 1994;83(4):931-938.
8. Gale RE, Wheadon H, Boulos P, Linch DC. Tissue specificity of X-chromosome inactivation patterns. Blood. 1994;83(10): 2899-2905.
9. Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol. 1997;98(3):512-519.
10. Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996; 88(1):59-65.
11. Abkowitz JL, Taboada M, Shelton GH, Catlin SN, Guttorp P, Kiklevich JV. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci USA. 1998;95(7):3862-3866.
12. Kristiansen M, Knudsen GP, Bathum L, et al. Twin study of genetic and aging effects on X chromosome inactivation. Eur J Hum Genet. 2005;13(5):599-606.
13. Kristiansen M, Helland A, Kristensen GB, et al. X chromosome inactivation in cervical cancer patients. Cancer Genet Cytogenet. 2003; 146(1):73-76.
14. Kristiansen M, Knudsen GP, Maguire P, et al. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet. 2005;42(11):877-880.
15. van Dijk JP, Heuver L, Stevens-Linders E, et al. Acquired skewing of Lyonization remains stable for a prolonged period in healthy blood donors. Leukemia. 2002;16(3):362-367.
16. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6): 642-650.
17. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44(6):651-658.
18. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
19. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012; 4(149):149ra118.
20. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014; 111(7):2548-2553.
21. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haemato-poietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508 (7496):420]. Nature. 2014;506(7488):328-333.
22. . Nature. 2014;506(7488):328-333.
23. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
24. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.
25. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12):1472-1478.
26. Sharp A, Robinson D, Jacobs P. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet. 2000;107(4):343-349.
27. Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet. 2013;14(9):618-630.
28. Lorthongpanich C, Cheow LF, Balu S, et al. Single-cell DNA-methylation analysis reveals epigenetic chimerism in preimplantation embryos. Science. 2013;341(6150):1110-1112.
29. Shlush LI, Chapal-Ilani N, Adar R, et al. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood. 2012;120(3):603-612.
30. Evrony GD, Cai X, Lee E, et al. Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell. 2012;151(3):483-496.
31. Pierre RV, Hoagland HC. Age-associated an-euploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer. 1972; 30(4):889-894.
32. United Kingdom Cancer Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic bone marrows [published correction appears in Genes Chromosomes Cancer. 1992;5(4):411]. Genes Chromosomes Cancer. 1992;5(1):83-88.
33. Genes Chromosomes Cancer. 1992;5(1):83-88.
34. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
35. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythe-mia and myelofibrosis. Leukemia. 2009;23(5): 905-911.
36. McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemo-poiesis. Cell Reports. 2015;10(8):1239-1245.
37. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.
38. Acuna-Hidalgo R, Sengul H, Steehouwer M, et al. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet. 2017;101(1):50-64.
39. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118(4): 1071-1077.
40. Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130(6):753-762.
41. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23-31.
42. Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442-454.
43. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.
44. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
45. Kunimoto H, Nakajima H. Epigenetic dysre-gulation of hematopoietic stem cells and preleukemic state. Int J Hematol. 2017;106(1): 34-44.
46. Mengel-From J, Thinggaard M, Christiansen L, Vaupel JW, Orstavik KH, Christensen K. Skewed X inactivation and survival: a 13-year follow-up study of elderly twins and singletons. Eur J Hum Genet. 2012;20(3):361-364.
47. Ju YS, Martincorena I, Gerstung M, et al. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature. 2017;543(7647):714-718.
48. Forsberg LA, Rasi C, Malmqvist N, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46(6): 624-628.
49. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3): 374-382.e4.
50. Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2016;2(3):370-372.
51. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552-555.
52. Ruark E, Snape K, Humburg P, et al; Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406-410.
53. Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann Med. 2010;42(6):394-403.
54. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327): 842-847.
55. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2):111-121.
56. Bonnefond A, Skrobek B, Lobbens S, et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet. 2013;45(9): 1040-1043.
57. Shlush LI, Minden MD. Preleukemia: the normal side of cancer. Curr Opin Hematol. 2015;22(2):77-84.
58. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014; 4(9):1088-1101.
59. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioim-munoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
60. Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016;128(9): 1246-1259.
61. Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547.
62. Gillis NK, Ball M, Zhang Q, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18(1):112-121.
63. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598-1605.
64. Yasuda T, Ueno T, Fukumura K, et al. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia. 2014;28(2):426-428.
65. Gibson CJ, Kennedy JA, Nikiforow S, et al. Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017;130(1): 91-94.
66. Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25):3371-3378.
67. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1): 35-47.
68. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20): 2391-2405.
69. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.